Date:
2026-05-26
Content:
The U.S. Food and Drug Administration (FDA) has released a new inspection report concerning Intas Pharmaceutical Limited, an India-based drug manufacturer.
The report, classified as a Form 483, follows a regulatory inspection of the company’s facilities conducted in late 2025. A Form 483 is typically issued when FDA investigators observe conditions that may violate federal safety and quality regulations. These observations often relate to manufacturing processes, quality control measures, or facility maintenance.
For pharmaceutical companies, receiving a Form 483 requires a timely and comprehensive response to address the cited issues. Failure to rectify these observations can lead to further regulatory action, including warning letters or import bans, to ensure that medications entering the U.S. market remain safe and effective.
Source: FDA CDER FOIA Electronic Reading Room
Link:
http://www.fda.gov/drugs/cder-foia-electronic-reading-room/intas-pharmaceutical-limited-09172025
Keywords:
FDA, Intas Pharmaceutical Limited, Form 483, Pharmaceutical Manufacturing, India, Drug Quality